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Research proposal:
Scientific dissemination:
• 2 or more publications in high-impact journals
• Results presentation in national and international congresses
Community dissemination:
• Project website creation
• Press releases and media interviews
DISSEMINATION PLAN
If the outcome of this research project results positive,
the proposed gene therapy could be sold to
pharmaceutical companies as a promising treatment for
Huntington’s disease either genetically diagnosed or first
symptomatic individuals.
FUTURE PERSPECTIVES
Huntington’s disease (HD) is a severe autosomal dominant
neurodegenerative disorder typically diagnosed between the ages
of 40 and 60. Clinically, it is characterized by a combination of
inevitably progressing motor, cognitive, and psychiatric symptoms
due to loss of GABAergic medium spiny neurons (MSNs) in the
striatum of the forebrain. There is no cure for HD so far, and death
usually occurs 5-20 years after the first clinical signs emerge.
Most HD individuals present solely one mutated allele with an
expanded CAG repeats in the HTT exon-1, leading to the production
of the deleterious mutant huntingtin protein (mHTT). Therefore,
allele-specific gene editing approaches deleting the mutated HTT
exon-1 could become a potential therapy for HD patients.
BACKGROUND
Allele-specific CRISPR/SaCas9 gene editing therapy targeting
the mutated HTT exon-1 would decrease the formation of mHTT
aggregates reducing the neuronal dysfunction and striatum
atrophy.
Objectives:
• All-in-one vector design with neuronal tropism
• In vitro reduction of mHTT aggregates in MSNs
• In vivo decrease of mHTT aggregates in HD mice models
• Therapeutic effect in HD mice models
HYPOTHESIS & OBJECTIVES
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